Citi's 2026 Virtual Oncology Leadership Summit February 18, 2026 10:45 AM ESTCompany ParticipantsSamarth Kulkarni - CEO ...

STUART, Fla.--(BUSINESS WIRE)--Cognigenics, a pioneering company in RNA-based therapeutics for neuropsychiatric conditions and neurocognitive disorders, announced the publication of its latest ...

Viral hemorrhagic septicemia virus or VHSV, is a single-stranded negative-sense RNA virus that is a member of the Rhabdoviridae family’s genus Novirhabdovirus. Its major host is rainbow trout. Severe ...

Polyglutamine (polyQ) diseases, a group of dominantly inherited CNS disorders, are caused by an abnormal expansion of cytosine-adenine-guanine repeats (usually over 35-40 repeats). PolyQ diseases, ...

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News: Celyad Oncology (Euronext: CYAD) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (the “Company”), today announces the publication of the ...

Background: In this study, we utilized a non-viral minicircle vector carrying two shRNA targeting sites. We hypothesis that double shRNA knockdown of PHD and AsPHD2 can be used for treatment of IHD by ...

Epigenetic mechanisms are involved in several cellular functions, and their role in the immune system is of prime importance. Histone deacetylases (HDACs) are an important set of enzymes that regulate ...

STUART, Fla.--(BUSINESS WIRE)-- Scientists from Cognigenics have made significant progress in developing precision-based therapeutics for neurological disorders. In a groundbreaking study, they ...

In an interview with Targeted Oncology, David E. Gilham, PhD, discussed the findings from the single vector multiplexed short-hairpin RNA approach to concurrently knockdown the expression of multiple ...